Zofková I, Bednár J
Research Institute of Endocrinology, Prague/Czechoslovakia.
Exp Clin Endocrinol. 1988 Mar;91(1):7-12.
Thyrotropin (TSH) secretion was assessed in three groups of healthy volunteers before and after four days administration of 1.25(OH)2 vitamin D3 (calcitriol) by the oral route -1.5 micrograms/d (group A), 3.0 micrograms/d (group B) or 3.0 micrograms/d combined with trifluoperazine (8-12 mg/d by mouth) (group C). The control trials and experiments proper were made in the same subjects within one month. The lower calcitriol dose did not change significantly the TRH-stimulated TSH levels nor the secretory reserve measured as the difference of TSH levels at the rest and TRH-stimulated levels (delta TSH) during the 20th, 30th, 40th and 60th minute following TRH administration. A larger calcitriol dose caused a significant increase of TSH values at rest and TRH-stimulated values during the 20th, 30th, 40th and 60th minute following TRH administration (p less than 0.05, p less than 0.05, p less than 0.05, p less than 0.05 and p less than 0.01, respectively) as well as delta TSH (p less than 0.05 at all time intervals). The intracellular calcium antagonist trifluoperazine interfered only with the stimulating effect of calcitriol on the TSH secretion at rest and on delta TSH during the 60th minute following TRH administration, while the TSH levels during the 20th, 30th, 40th and 60th minute after TRH administration were significantly higher, as compared with the control examination (p less than 0.01, p less than 0.01, p less than 0.05 and p less than 0.05, respectively) and also delta TSH was significantly elevated during 20th, 30th, and 40th minute after TRH administration during combined treatment (p less than 0.05, p less than 0.01, p less than 0.05, respectively). Calcitriol thus causes a dose-dependent increase of TSH secretion, probably partly also by a mechanism which is independent on the change of intracellular calcium homeostasis.
对三组健康志愿者口服1.25(OH)2维生素D3(骨化三醇),剂量分别为1.5微克/天(A组)、3.0微克/天(B组)或3.0微克/天联合三氟拉嗪(口服8 - 12毫克/天)(C组),持续四天,在给药前后评估促甲状腺激素(TSH)分泌。对照试验和正式实验在同一受试者一个月内完成。较低剂量的骨化三醇并未显著改变促甲状腺激素释放激素(TRH)刺激后的TSH水平,也未改变以TRH给药后第20、30、40和60分钟时静息状态下TSH水平与TRH刺激后TSH水平之差(△TSH)来衡量的分泌储备。较高剂量的骨化三醇导致TRH给药后第20、30、40和60分钟时静息状态下TSH值以及TRH刺激后的TSH值显著升高(分别为p<0.05、p<0.05、p<0.05、p<0.05和p<0.01),△TSH也升高(所有时间间隔均为p<0.05)。细胞内钙拮抗剂三氟拉嗪仅在TRH给药后第60分钟时干扰骨化三醇对静息状态下TSH分泌以及△TSH的刺激作用,而TRH给药后第20、30、40和60分钟时的TSH水平与对照检查相比显著更高(分别为p<0.01、p<0.01、p<0.05和p<0.05),联合治疗期间TRH给药后第20、30和40分钟时△TSH也显著升高(分别为p<0.05、p<0.01、p<0.05)。因此,骨化三醇可导致TSH分泌呈剂量依赖性增加,可能部分也是通过一种不依赖细胞内钙稳态变化的机制实现的。